PECAM1 and myeloid sarcoma: EMPs (identified by flow cytometry as < 3.0 um in diameter, and CD31+/CD42b− or CD62E+) in platelet poor plasma (PPP) from patients with different clinical forms of MS—RRMS, primary progressive MS, secondary progressive MS, and CSI—were all found to be elevated when compared to healthy controls [119].